View printer-friendly version

ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it will present at the Wilsons Healthcare IT Conference in Sydney on Wednesday, 30th November 2016 at 9:45am AEDT.

The goal of the conference is to demonstrate how technology can improve the efficiency of healthcare spending and enhance outcomes for patients. The invitation-only event will be attended by approximately 40 institutional investors who are new to healthcare IT and e-health investment opportunities and looking to gain a more in-depth understanding of the sector.

ResApp also advises that the startup of its US clinical study, SMARTCOUGH-C, is progressing well with recruitment to begin this quarter. Details of the study are now available on the US National Institutes of Health clinical trials database at www.clinicaltrials.gov (NCT02973282). Institutional review board approvals are in place, and Site Initiation Visits at the main sites and their multiple satellite sites will take place shortly, during which clinical staff will be trained on the final approved protocol. The Company expects rapid recruitment given the size of the participating hospitals and the onset of winter in the US when there is a high prevalence of respiratory disease.

– ENDS –

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au.

CONTACT
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

SHAREHOLDER & MEDIA CONTACT
Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2017 ResApp Health Limited. All Rights Reserved.

CONTACT US

+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

      

LEGAL

Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.